Chen Xiaoyuan, Lu Yiwei, Shi Xiaoli, Han Guoyong, Zhang Long, Ni Chuangye, Zhao Jie, Gao Yun, Wang Xuehao
Hepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, Nanjing, China.
Front Oncol. 2022 Apr 8;12:864106. doi: 10.3389/fonc.2022.864106. eCollection 2022.
Hepatocellular carcinoma (HCC) is a highly heterogeneous tumor with several rare pathological subtypes and which is still poorly understood. This study aimed to describe the epidemiological and clinical spectrum of five rare HCC subtypes and develop a competing risk nomogram for cancer-specific survival prediction.
The study cohort was recruited from the Surveillance, Epidemiology, and End Results database. The clinicopathological data of 50,218 patients histologically diagnosed with classic HCC and five rare subtypes (ICD-O-3 Histology Code = 8170/3-8175/3) between 2004 and 2018 were reviewed. The annual percent change (APC) was calculated utilizing Joinpoint regression. The nomogram was developed based on multivariable competing risk survival analyses. Akaike information criterion, Bayesian information criterion, C-index, calibration curve, and area under the receiver operating characteristic curve were obtained to evaluate the prognostic performance. A decision curve analysis was introduced to examine the clinical value of the models.
Despite scirrhous carcinoma, which showed a decreasing trend (APC = -6.8%, = 0.025), the morbidity of other rare subtypes remained stable from 2004 to 2018. The incidence-based mortality was plateau in all subtypes during the period. Clear cell carcinoma is the most common subtype ( = 551, 1.1%), followed by subtypes of fibrolamellar ( = 241, 0.5%), scirrhous ( = 82, 0.2%), spindle cell ( = 61, 0.1%), and pleomorphic ( = 17, ~0%). The patients with fibrolamellar carcinoma were younger and more likely to have a non-cirrhotic liver and better prognoses. Scirrhous carcinoma shared almost the same macro-clinical characteristics and outcomes as the classic HCC. Clear cell carcinoma tended to occur in the Asia-Pacific elderly male population, and more than half of them were large HCC (Size>5cm). Sarcomatoid (including spindle cell and pleomorphic) carcinoma was associated with a larger tumor size, poorer differentiation, and more dismal prognoses. The pathological subtype, T stage, M stage, surgery, alpha-fetoprotein, and cancer history were confirmed as the independent predictors in patients with rare subtypes. The nomogram showed good calibration, discrimination, and net benefits in clinical practice.
The rare subtypes had unique clinicopathological features and biological behaviors compared with the classic HCC. Our findings could provide a valuable reference for clinicians. The constructed nomogram could predict the prognoses with good performance, which is meaningful to individualized management.
肝细胞癌(HCC)是一种高度异质性肿瘤,有几种罕见的病理亚型,目前仍了解不足。本研究旨在描述五种罕见HCC亚型的流行病学和临床特征,并开发一种竞争风险列线图以预测癌症特异性生存。
研究队列来自监测、流行病学和最终结果数据库。回顾了2004年至2018年间组织学诊断为经典HCC和五种罕见亚型(ICD-O-3组织学编码=8170/3 - 8175/3)的50218例患者的临床病理数据。利用Joinpoint回归计算年度百分比变化(APC)。基于多变量竞争风险生存分析开发列线图。获得赤池信息准则、贝叶斯信息准则、C指数、校准曲线和受试者操作特征曲线下面积以评估预后性能。引入决策曲线分析以检验模型的临床价值。
尽管硬化型癌呈下降趋势(APC=-6.8%,P=0.025),但2004年至2018年其他罕见亚型的发病率保持稳定。在此期间,所有亚型基于发病率的死亡率均处于平台期。透明细胞癌是最常见的亚型(n=551,1.1%),其次是纤维板层型(n=241,0.5%)、硬化型(n=82,0.2%)、梭形细胞型(n=61,0.1%)和多形型(n=17,~0%)。纤维板层癌患者较年轻,更可能有非肝硬化肝脏且预后较好。硬化型癌与经典HCC的宏观临床特征和结局几乎相同。透明细胞癌倾向于发生在亚太地区老年男性人群中,其中一半以上为大肝癌(大小>5cm)。肉瘤样(包括梭形细胞和多形型)癌与更大的肿瘤大小、更差的分化程度和更差的预后相关。病理亚型、T分期、M分期、手术、甲胎蛋白和癌症史被确认为罕见亚型患者的独立预测因素。列线图在临床实践中显示出良好的校准、区分度和净效益。
与经典HCC相比,罕见亚型具有独特的临床病理特征和生物学行为。我们的研究结果可为临床医生提供有价值的参考。构建的列线图能够较好地预测预后,对个体化管理具有重要意义。